Peptide record

TPDB44900

gH625Cys Antiviral Blood-Brain Barrier modified_plain modified
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB44900
gH625Cys
Antiviral Blood-Brain Barrier
Anti-infective peptides Delivery and barrier-penetrating peptides
AI4AVP Peptipedia B3Pred BBPpredict
modified_plain
Yes
A 20-aa modified multi-activity (Antiviral and Blood-Brain Barrier) peptide sequence curated from AI4AVP, Peptipedia, B3Pred, and other sources, with an available 3D structural model.
C-terminal: Cys-CONH2 group is attached at C-terminal N-terminal: Acetylaed at N-terminal
Sequence
HGLASTLTRWAHYNALIRAF
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
20 reviewed residue count
Cys-CONH2 group is attached at C-terminal Activity
Linear Activity
Acetylaed at N-terminal Activity
HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPhe Activity
N[C@@]([H])(CC1=CN=C-N1)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O Activity
Evidence Records 1 records
Evidence 1 Activity

Activity

Blood-Brain Barrier

Target

BMECs

Assay & Model

5 micromolar
Fluorescence microscopy
Liposomes preparations were non-toxic for the endothelial cells and improves the transfer of liposom
Fluorescence microscopy
gH625 ameliorates the efficiency of liposomes to deliver. PACAP

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
gH625-liposomes represent a promising strategy to deliver therapeutic agents to CNS and to provide a
Comined with liposome
Additional Detail Fields 1 fields
Intravenous